Again... Another fantastic news from ANP!!New Muscle Disease...

Again... Another fantastic news from ANP!!

New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2
• LGMDR2, also referred to as dysferlinopathy, is a rare genetic muscle disease caused by mutations in the dysferlin gene (DYSF)
• Animal study conducted at MCRI in collaboration with Jain Foundation in the US
• Study results showed significant decreases in target CD49d RNA and key immune cell RNA levels in the muscle

The use of ATL1102 as a treatment for dysferlinopathy is covered in ANP’s patent application PCTAU2020/050445 directed at modifying muscle performance by reducing muscle adiposity. The recently filed provisional application 2021903024 also claims the use of ATL1102 to reduce thrombospondin-1 reported to be beneficial in treating the disease. The data from Bla/J mice studies can be used to support the prosecution of these claims and the filing of a new patent application.

Save and Sound:
"....There are several genetic muscle diseases with similar immune cell involvement like in LGMDR2 and DMD and so this data points to the potential use of low dose of ATL1102 as a treatment for such conditions."Dr George Tachas Ph.D., Director, Drug Discovery and Patents at Antisense Therapeutic.

"...we at the Jain Foundation are pleased to be working with Antisense Therapeutics and the MCRI on their research program evaluating the antisense to CD49d drug as a possible treatment of dysferlinopathy."Laura Rufibach, Co-President of the Jain Foundation.

"... very pleased to be involved with the hope that such endeavors may help a population in great need of an effective treatment." Associate Professor Alastair Corbett, Neurologist at the Concord Repatriation General Hospital Neurology Clinic